"When the first BTK inhibitor got approved by the FDA for other conditions, we all saw that follicular lymphoma should be the ...

A Phase I study included 13 patients with a variety of relapsed B-cell NHL (five follicular, three mantle cell, three DLBCL, two chronic lymphocytic leukemia/small-cell lymphoma [CLL/SLL]).

It is defined as a lymphoma of follicle center B-cells (centrocytes and centroblasts), which has at least a partially follicular pattern. It is positive for the B-cell markers CD10, CD19 ...

The spleen is a very important large lymphoid organ consisting of the so-called red pulp which contains macrophages and other cellular elements and is richly bathed in blood entering from a network of ...

For many decades, the foundations of cancer treatment have been surgery, chemotherapy, and radiation therapy. But, in recent years, a newer therapy in the form of immunotherapy has emerged, ...

Follicular lymphoma -- typically a slow-growing or indolent form of non-Hodgkin lymphoma that arises from B lymphocytes -- accounts ... Hodgkin lymphoma or mantle cell lymphoma compared with ...

Follicular lymphoma is a slow growing cancer of the lymph nodes. It is the most common form of slow growing B-cell non-Hodgkin’s lymphoma.

B cells, naive follicular B cells, and marginal-zone B cells. 2 However, the development of memory B cells, plasma cells, and B1 cells (an important B-cell subset in mice but not humans ...

In a recent Phase II study, 46 relapsed patients with indolent or aggressive B-cell NHL (the majority with follicular lymphoma) received oblimersen combined with rituximab. [75] Responses were ...

When I started receiving treatment for follicular lymphoma, I wasn’t sure what to expect regarding treatment — and a lot of things were unexpected. I’ve heard that trauma doesn’t make people stronger, ...